Intravenous danavorexton (TAK-925), an OX2R-selective agonist, improves objective and subjective sleepiness and vigilance across models and early human studies; oral oveporexton (TAK-861) has shown Phase 2 efficacy in NT1 with clinically meaningful reductions in EDS and cataplexy, marking a shift from symptomatic control to mechanistically targeted therapy [59,60]. Here, HCRTR2 is linked to Cataplexy.